Short Interest in Atossa Genetics Inc. (NASDAQ:ATOS) Rises By 29.7%

Atossa Genetics Inc. (NASDAQ:ATOS) was the target of a significant increase in short interest in January. As of January 30th, there was short interest totaling 4,696,759 shares, an increase of 29.7% from the January 15th total of 3,621,023 shares. Approximately 60.2% of the company’s stock are sold short. Based on an average daily volume of 2,992,317 shares, the days-to-cover ratio is currently 1.6 days. Based on an average daily volume of 2,992,317 shares, the days-to-cover ratio is currently 1.6 days. Approximately 60.2% of the company’s stock are sold short.

Hedge Funds Weigh In On Atossa Genetics

Institutional investors and hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC raised its position in shares of Atossa Genetics by 0.7% in the fourth quarter. Geode Capital Management LLC now owns 1,371,909 shares of the company’s stock valued at $810,000 after buying an additional 9,627 shares in the last quarter. Hudson Bay Capital Management LP bought a new position in Atossa Genetics during the 2nd quarter worth $26,000. Gallagher Capital Advisors LLC bought a new position in Atossa Genetics during the 3rd quarter worth $27,000. JPMorgan Chase & Co. raised its holdings in Atossa Genetics by 1,294.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 38,215 shares of the company’s stock valued at $33,000 after acquiring an additional 35,474 shares in the last quarter. Finally, Bank of America Corp DE lifted its position in shares of Atossa Genetics by 55.7% during the 2nd quarter. Bank of America Corp DE now owns 99,601 shares of the company’s stock valued at $83,000 after acquiring an additional 35,629 shares during the period. Institutional investors and hedge funds own 12.74% of the company’s stock.

Atossa Genetics Trading Up 6.6%

ATOS opened at $4.20 on Tuesday. The stock’s fifty day simple moving average is $8.89 and its 200 day simple moving average is $11.31. Atossa Genetics has a 1-year low of $3.76 and a 1-year high of $19.35. The stock has a market cap of $36.20 million, a PE ratio of -1.17 and a beta of 1.36.

Analyst Upgrades and Downgrades

Several brokerages have commented on ATOS. Ascendiant Capital Markets boosted their price target on shares of Atossa Genetics from $116.25 to $120.00 and gave the stock a “buy” rating in a research report on Monday, December 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Atossa Genetics in a report on Wednesday, January 21st. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, Atossa Genetics currently has a consensus rating of “Hold” and an average price target of $95.00.

Atossa Genetics Company Profile

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.